Supernus Triggers MACD Death Cross, KDJ Death Cross on 15-Minute Chart.
ByAinvest
Monday, Jul 7, 2025 3:37 pm ET1min read
AZN--
RedHill Biopharma (RDHL) shares rose 5.8% after the company announced it has started patient recruitment for a phase 2 trial of opaganib in combination with darolutamide for the treatment of metastatic castrate-resistant prostate cancer [1]. AstraZeneca (AZN) gained 2.2% following reports that its Chief Executive, Pascal Soriot, has expressed a preference to move the company's stock market listing to the US [1].
IGM Biosciences (IGMS) shares jumped 15% after the firm announced it has agreed to be acquired by Concentra Biosciences [1]. Sage Therapeutics (SAGE) shares were down 0.2% as the company agreed to be acquired by Supernus Pharmaceuticals (SUPN), with Supernus adding 0.9% [1].
Based on the analysis of Supernus's 15-minute chart, a MACD Death Cross and KDJ Death Cross were triggered on July 7th, 2025, at 15:30. This indicates that the stock price has a high potential to continue declining, as the momentum of the stock price is shifting towards the downside and may lead to further decreases [2].
References:
[1] https://finance.yahoo.com/news/sector-health-care-stocks-rise-195638369.html
[2] Based on the analysis of Supernus's 15-minute chart, a MACD Death Cross and KDJ Death Cross were triggered on July 7th, 2025, at 15:30. This indicates that the stock price has a high potential to continue declining, as the momentum of the stock price is shifting towards the downside and may lead to further decreases.
IGMS--
RDHL--
SAGE--
SUPN--
Based on the analysis of Supernus's 15-minute chart, a MACD Death Cross and KDJ Death Cross were triggered on July 7th, 2025 at 15:30. This indicates that the stock price has a high potential to continue declining, as the momentum of the stock price is shifting towards the downside and may lead to further decreases.
Health care stocks experienced a mixed performance on Tuesday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each climbing 1.4% [1]. The iShares Biotechnology ETF (IBB) added 0.9% to the gains.RedHill Biopharma (RDHL) shares rose 5.8% after the company announced it has started patient recruitment for a phase 2 trial of opaganib in combination with darolutamide for the treatment of metastatic castrate-resistant prostate cancer [1]. AstraZeneca (AZN) gained 2.2% following reports that its Chief Executive, Pascal Soriot, has expressed a preference to move the company's stock market listing to the US [1].
IGM Biosciences (IGMS) shares jumped 15% after the firm announced it has agreed to be acquired by Concentra Biosciences [1]. Sage Therapeutics (SAGE) shares were down 0.2% as the company agreed to be acquired by Supernus Pharmaceuticals (SUPN), with Supernus adding 0.9% [1].
Based on the analysis of Supernus's 15-minute chart, a MACD Death Cross and KDJ Death Cross were triggered on July 7th, 2025, at 15:30. This indicates that the stock price has a high potential to continue declining, as the momentum of the stock price is shifting towards the downside and may lead to further decreases [2].
References:
[1] https://finance.yahoo.com/news/sector-health-care-stocks-rise-195638369.html
[2] Based on the analysis of Supernus's 15-minute chart, a MACD Death Cross and KDJ Death Cross were triggered on July 7th, 2025, at 15:30. This indicates that the stock price has a high potential to continue declining, as the momentum of the stock price is shifting towards the downside and may lead to further decreases.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet